Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalpiciclib + endocrine therapy with concurrent radiotherapy for early HR+/HER2- breast cancer
ChiCTR2400085859Phase 2Recruiting
- Sponsor
- Shanxi Cancer Hospital
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dalpiciclib in breast cancer, sponsored by Shanxi Cancer Hospital. Primary endpoint: Incidence of ≥ grade 3 adverse events. Started Jun 2024; status: recruiting.
02
Drugs
dalpiciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2400085859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085859.